86 related articles for article (PubMed ID: 22262189)
1. Polo-like kinase 2: a new exploitable target to undermine mutant p53-dependent chemoresistance.
Napoli M; Girardini JE; Del Sal G
Cell Cycle; 2012 Feb; 11(3):438. PubMed ID: 22262189
[No Abstract] [Full Text] [Related]
2. Mutant p53 subverts PLK2 function in a novel, reinforced loop of corruption.
Haupt S; Haupt Y
Cell Cycle; 2012 Jan; 11(2):217-8. PubMed ID: 22214663
[No Abstract] [Full Text] [Related]
3. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop.
Valenti F; Fausti F; Biagioni F; Shay T; Fontemaggi G; Domany E; Yaffe MB; Strano S; Blandino G; Di Agostino S
Cell Cycle; 2011 Dec; 10(24):4330-40. PubMed ID: 22134238
[TBL] [Abstract][Full Text] [Related]
4. Chk2 meets Plk3 in damage control.
Herzog CR
Cell Cycle; 2002; 1(6):408-9. PubMed ID: 12548016
[No Abstract] [Full Text] [Related]
5. The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR.
Park BJ; Kang JW; Lee SW; Choi SJ; Shin YK; Ahn YH; Choi YH; Choi D; Lee KS; Kim S
Cell; 2005 Jan; 120(2):209-21. PubMed ID: 15680327
[TBL] [Abstract][Full Text] [Related]
6. Degradation of a non-cycling mammalian polo-like kinase.
Dai W
Cell Cycle; 2004 May; 3(5):625-6. PubMed ID: 15107610
[No Abstract] [Full Text] [Related]
7. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.
Maya R; Balass M; Kim ST; Shkedy D; Leal JF; Shifman O; Moas M; Buschmann T; Ronai Z; Shiloh Y; Kastan MB; Katzir E; Oren M
Genes Dev; 2001 May; 15(9):1067-77. PubMed ID: 11331603
[TBL] [Abstract][Full Text] [Related]
8. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage.
Khosravi R; Maya R; Gottlieb T; Oren M; Shiloh Y; Shkedy D
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14973-7. PubMed ID: 10611322
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic hints from analyzing the attractor landscape of the p53 regulatory circuit.
Wang W
Sci Signal; 2013 Feb; 6(261):pe5. PubMed ID: 23386744
[TBL] [Abstract][Full Text] [Related]
10. p53 Suppresses E2F1-dependent PLK1 expression upon DNA damage by forming p53-E2F1-DNA complex.
Zhou Z; Cao JX; Li SY; An GS; Ni JH; Jia HT
Exp Cell Res; 2013 Dec; 319(20):3104-15. PubMed ID: 24076372
[TBL] [Abstract][Full Text] [Related]
11. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A; Masterson P; O'Connor MJ; Jackson SP
Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase inhibitor coralyne photosensitizes DNA, leading to elicitation of Chk2-dependent S-phase checkpoint and p53-independent apoptosis in cancer cells.
Patro BS; Maity B; Chattopadhyay S
Antioxid Redox Signal; 2010 Apr; 12(8):945-60. PubMed ID: 19922265
[TBL] [Abstract][Full Text] [Related]
14. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
15. Mdmx and Mdm2: brothers in arms?
Marine JC; Jochemsen AG
Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
[TBL] [Abstract][Full Text] [Related]
16. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage.
Di Stefano V; Soddu S; Sacchi A; D'Orazi G
Oncogene; 2005 Aug; 24(35):5431-42. PubMed ID: 15897882
[TBL] [Abstract][Full Text] [Related]
17. Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response.
Li Z; Li J; Kong Y; Yan S; Ahmad N; Liu X
Cancer Res; 2017 Jun; 77(12):3169-3180. PubMed ID: 28512243
[TBL] [Abstract][Full Text] [Related]
18. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
19. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
[TBL] [Abstract][Full Text] [Related]
20. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2.
Xie S; Wu H; Wang Q; Kunicki J; Thomas RO; Hollingsworth RE; Cogswell J; Dai W
Cell Cycle; 2002; 1(6):424-9. PubMed ID: 12548019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
